Physician profile
David N Bartov
NPI 1467616664
$12,274.27
in general payments reported to CMS, 2019-2025
42 companies · $1,288 in 2025
The $1,288 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,304 · 2020: $1,122 · 2021: $1,715 · 2022: $2,422 · 2023: $1,964 · 2024: $1,459 · 2025: $1,288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,689 · Entertainment: $21.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,689.40 |
| Entertainment | $21.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,329.74 | 2019-2025 | Xience Skypoint, Diamondback Coronary, Optis |
| Cardiovascular Systems INC. | $1,607.42 | 2019-2023 | |
| Penumbra, INC. | $1,205.58 | 2019-2024 | Indigo System |
| Medtronic, INC. | $1,151.60 | 2021-2025 | Onyx Frontier, Symplicity G3, Ffrangio |
| Shockwave Medical, INC | $852.50 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boston Scientific Corporation | $749.37 | 2019-2025 | Filterwire Ez |
| Amgen INC. | $505.36 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $305.00 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $276.27 | 2019-2025 | Farxiga |
| Abiomed | $275.52 | 2021-2025 | Impella |
| E.R. Squibb & Sons, L.L.C. | $240.32 | 2019-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $238.45 | 2021-2025 | Verquvo |
| Pfizer INC. | $230.19 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $226.43 | 2019-2025 | |
| Atricure, INC. | $182.11 | 2019-2025 | Atriclip Laa Exclusion System |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $158.92 | 2019-2023 | |
| Siemens Medical Solutions USA, INC. | $158.87 | 2024 | |
| Medtronic Vascular, INC. | $157.48 | 2019-2020 | |
| Chiesi USA, INC. | $144.60 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $132.55 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $132.15 | 2021-2025 | Lifevest |
| Irhythm Technologies, INC. | $105.81 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Cardiva Medical, INC. | $101.82 | 2021-2024 | Other, Optowire |
| Novo Nordisk INC | $90.48 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Esperion Therapeutics, INC. | $86.75 | 2021-2025 | Nexletol |
| Baxter Healthcare | $86.61 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Opsens INC. | $81.10 | 2021-2023 | Optowire |
| Cvrx, INC. | $54.17 | 2024 | Barostim Neo System |
| Azurity Pharmaceuticals, INC. | $51.38 | 2024 | Edarbyclor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.19 | 2019-2024 | Jardiance |
| Acist Medical Systems, INC. | $50.11 | 2022-2023 | |
| Kiniksa Pharmaceuticals, LTD. | $41.60 | 2022-2023 | Arcalyst |
| W. L. Gore & Associates, INC. | $35.58 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $29.29 | 2019 | |
| Heartflow, INC. | $24.87 | 2023 | Ffrct |
| Bayer Healthcare Pharmaceuticals INC. | $24.46 | 2025 | |
| Lilly USA, LLC | $21.37 | 2025 | Zepbound, Mounjaro |
| Kiniksa Pharmaceuticals International, Plc | $17.99 | 2024 | Arcalyst |
| Bridgebio Pharma, INC. | $16.46 | 2025 | Attruby |
| Terumo Medical Corporation | $15.05 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.89 | 2019 | |
| Lundbeck LLC | $13.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bartov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.